Long-term treatment of schizoaffective disorder: Review and recommendations

Pharmacopsychiatry

Volumn 36, Issue 2, 2003, Pages 45-56

  Baethge, Christopher ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Long term treatment; Maintenance therapy; Prophylaxis; Review; Schizoaffective disorder

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; IMIPRAMINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE; VALPROIC ACID;

CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; FOLLOW UP; HUMAN; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MONOTHERAPY; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOPHARMACOTHERAPY; RATING SCALE; RELAPSE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT OUTCOME;

ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; HEALTH PLANNING GUIDELINES; HUMANS; PSYCHOTIC DISORDERS; TIME; TIME FACTORS;

EID: 0038293347     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-39045     Document Type: Review

References (78)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd edn. revised (DSM-III-R). Washington, DC: APA, 1987
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edn. (DSM-IV). Washington, DC: APA, 1994
3. Angst J, Preisig M. Course of a clinical cohort of unipolar, bipolar and schizoaffective patients. Results of a prospective study from 1959 to 1985. Schweiz Arch für Neurol und Psychiat 1995; 146: 5-16
4. Angst J, Preisig M. Outcome of a clinical cohort of unipolar, bipolar and schizoaffective patients. Results of a prospective study from 1959 to 1985. Schweiz Arch für Neurol und Psychiat 1995; 146: 17-23
5. Angst J, Weis P, Grof P, Baastrup C, Schou M. Lithium prophylaxis in recurrent affective disorders. Br J Psychiatry 1970; 116: 604-613
6. Angst J, Dittrich A, Grof P. Course of endogenous affective psychoses and its modification by prophylactic administration of imipramine and lithium. Int Pharmacopsychiat 1969; 2: 1-11
7. Aronoff MS, Epstein RS. Factors associated with poor response to lithium carbonate: A clinical study. Am J Psychiatry 1970; 127: 472-480
8. Baastrup PC, Schou M. Lithium as a prophylactic agent. Arch Gen Psychiatry 1967; 16: 162-172
9. Baethge C, Gruschka P, Berghöfer A, Bauer M, Müller-Oerlinghausen B, Bschor T, Smolka MN. Prophylaxis of schizoaffective disorder with lithium or carbamazepine: outcome after long-term follow-up. J Affect Disord 2002, in press
10. Banov MD, Zarate CA, Tohen M, Scialabba D, Wines JD, Kolbrener M, Kim JW, Cole JO. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry 1994; 55: 295-300
11. Bellaire W, Demisch K, Stoll KD. Carbamazepin vs. lithium. Münch Med Wschr 1990; 132 (Suppl 1): S82-86
12. Bocchetta A, Chilotti C, Severino G, Ardau R, del Zompo L. Carbamazepine Augmentation in lithium-refractory bipolar patients: a prospective study on long-term prophylactic effectiveness. J Clin Psychopharmacol 1997; 17: 92-96
13. Bogan AM, Brown ES, Suppes T. Efficacy of divalproex therapy for schizoaffective disorder. J Clin Psychopharmacol 2000; 20: 520-522
14. Bouman TK, Niemantsverdriet-van Kampen JK, Ormel J, Sloof CJ. The Effectiveness of lithium prophylaxis in bipolar and unipolar depressions and schizo-affective disorders. J Affect Disord 1986; 11: 275-280
15. Cabras PL, Hardoy J, Hardoy MC, Carta MG. Clinical experience with gabapentin in patients with bipolar and schizoaffective disorder: Results of an open-label study. J Clin Psychiatry 1999; 60: 245-248
16. Cochrane Collaboration. The Cochrane Controlled Trials Register. The Cochrane Collaboration, 2001; Issue 4
17. Ciapparelli A, Dell'Osso L, Pini S, Chiavacci MC, Fenzi M, Cassano GB. Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: A 24-months naturalistic study. J Clin Psychiatry 2000; 61: 329-334
18. DelBello MP, Lopez-Larson MP, Getz GE, Strakowski SM. Treatment of schizoaffective disorder with divalproex sodium (letter). Schizoph Res 2000; 46: 77-7
19. Delva NJ, Letemendia FJJ. Lithum in schizophrenia and schizo-affective disorders. Br J Psychiatry 1982; 141: 387-400
20. Dwight MM, Keck PE, Stanton SP, Strakowski SM, McElroy SL. Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder. Lancet 1994; 344: 554-555
21. Egli H. Erfahrungen mit der Lithiumprophylaxe phasischer affektiver Erkrankungen in einer psychiatrischen Poliklinik. Schweiz Med Wschr 1971; 101: 157-164
22. Emrich HM. Alternatives to lithium prophylaxis for affective and schizoaffective disorders. In: Marneros A, Tsuang MT (Eds.). Affective and Schizoaffective Disorders Berlin: Springer-Verlag, 1990: p. 262-273
23. Emrich HM, Dose M, von Zerssen D. The use of sodium valproate, carbamazeoine and oxcarbazepine in patients with affective disorders. J Affect Disord 1985; 8: 243-250
24. Faraone SV, Blehar M, Pepple J, Moldin SO, Norton J, Nurnberger JI, Malaspina D, Kaufmann CA, Reich T, Cloninger CR, DePaulo JR, Berg K, Gershon ES, Kirch DG, Tsuang MT. Diagnostic accuracy and confusability analyses: An application to the diagnostic interview for genetic studies. Psychol Med 1996; 26: 401-410
25. Fenn HH, Robinson D, Luby V, Dangel C, Buxton E, Beattie M, Kraemer H, Yesavage JA. Trends in pharmacotherapy of schizoaffective and bipolar affective disorders: A 5-year naturalistic study. Am J Psychiatry 1996; 153: 711-771
26. Frankenburg FR, Zanarini MC. Uses of clozapine in nonschizophrenic patients. Harvard Rev Psychiatry 1994; 2: 142-150
27. Ghaemi SN. New treatments for bipolar disorder: the role of atypical neuroleptic agents. J Clin Psychiatry 2000; 61 (suppl 14): 33-42
28. Ghaemi NS, Goodwin FK. Use of atypical antipsychotic agents in bipolar and schizoaffective disorders: Review of the empirical literature. J Clin Psychopharmacol 1999; 19: 354-361
29. Goodnick PJ, Meltzer HY. Treatment of schizoaffective disorders. Schizophr Bull 1984; 10: 30-48
30. Greil W, Ludwig-Mayerhofer W, Erazo N, Engel RR, Czernik A, Giedcke H, Müller-Oerlinghausen B, Osterheider M, Rudolf GAE, Sauer H, Tegeler J, Wetterling T. Lithium vs. carbamazepine in the maintenance treatment of schizoaffective disorder: a randomised study. Eur Arch Psychiatry Clin Neurosci 1997; 247: 42-50
31. Grossman LS, Harrow M, Goldberg JF, Fichtner CG. Outcome of schizoaffective disorder at two long-term follow-ups: Comparison with outcome of schizophrenia and affective disorders. Am J Psychiatry 1991; 148: 1359-1365
32. Grossman L, Harrow M, Lechert F, Meltzer HY. The Longitudinal course of schizoaffective disorders. J Nerv Ment Dis 1984; 172: 140-149
33. Hayes SG. Long-term use of valproate in primary psychiatric disorders. J Clin Psychiatry; 50 (3, Suppl): 35-39
34. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994; 151: 1409-1416
35. Hofmann G, Kremser M, Katschnig H, Schreiber V. Prophylaktische Lithiumtherapie bei manisch-depressivem Krankheitsgeschehen und bei Legierungspsychosen. Int Pharmacopsychiat 1970; 4: 187-193
36. Kando JC, Tohen M, Castillo J, Centorrino F. Concurrent use of clozapine and valproate in affective and psychotic disorders. J Clin Psychiatry 1994; 55: 255-257
37. Koufen H, Consbruch U. Langzeitkatamnese zur Frage von Nutzen und Nebenwirkungen der Lithiumprophylaxe der phasischen Psychosen. Fortschr Neurol Psychiat 1989; 57: 374-382
38. Küfferle B, Lenz G. Classification and course of schizo-affective psychoses. Psychiatrica Clin 1983; 16: 169-177
39. Lambert PA. Acute and prophylactic therapies of patients with affective disorderss using valpromide (dipropylacetamide). In: Emrich HM, Kuma T, Müller AA. Anticonvulsants in Affective Disorders Amsterdam: Excerpta Medica, 1984: p. 33-44
40. Leppig M, Bosch B, Naber D, Hippius H. Clozapine in the treatment of 121 out-patients. Psychopharmacology (Berl) 1989; 99: S77-79
41. Levinson DF, Umapathy C, Musthaq M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Am J Psychiatry 1999; 156: 1138-1148
42. Levitt JJ, Tsuang MT. The heterogeneity of schizoaffective disorder: implications for treatment. Am J Psychiatry 1988; 145: 926-936
43. Lindström LH. A retrospective study on the long-term efficacy of clozapine in 96 schizophrenic and schizoaffective patients during a 13-year period. Psychopharmacology (Berl) 1989; 99: S84-86
44. Lowe MR, Batchelor DH. Lithium and neuroleptics in the management of manic depressive psychosis. Human Psychopharmacology 1990; 5: 267-274
45. Maj M, Pirozzi R, Formicula RM, Bartoli L, Bucci P. Reliability and validity of the DSM-IV diagnostic category of schizoaffective disorder: Preliminary data. J Affect Disord 2000; 57: 95-98
46. Maj M, Perris C. Patterns of course in patients with a cross-sectional diagnosis of schizoaffective disorder. J Affect Disord 1990; 20: 71-77
47. Maj M. Lithium prophylaxis of schizoaffective disorders: a propspective study. J Affect Disord 1988; 14: 129-135
48. Mattes JA, Nayak D. Lithium versus fluphenazine for prophylaxis in mainly schizophrenic schizo-affectives. Biol Psychiatry 1984; 19: 445-449
49. McElroy SL, Keck PE, Strakowski SM. An overview of the treatment of schizoaffective disorder. J Clin Psychiatry 1999; 60 (Suppl 5): 16-21
50. McElroy SL, Dessain EC, Pope HG, Cole JO, Keck PE, Frankenberg FA, Aizley HG, O'Brien S. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 1991; 52: 411-414
51. Minnai GP, Tundo A. Effects of lithium on the course and symptoms of schizo-affective disorder. Lithium 1990; 1: 191-193
52. Narendran R, Young CM, Valenti AM, Pristach CA, Pato MT, Grace JJ. Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study. J Clin Psychiatry 2001; 62: 509-516
53. Owen RR, Beake BJ, Marby D, Dessain EC, Cole JO. Response to clozapine in chronic psychotic patients. Psychopharmacology Bull 1989; 25: 253-256
54. Perris C. Morbidity Suppressive effect of lithium carbonate in cycloid psychosis. Arch Gen Psychiatry, 1978: 328-331
55. th World Congress of Psychiatry. Pharmacopsychiatry 1983; Vol. 3: 375-380
56. Placidi GF, Lenzi A, Lazzerini F, Cassano GB, Akiskal HS. The comparative efficacy and safety of carbamazepine versus lithium: A randomized, double-blind 3-year trial in 83 patients. J Clin Psychiatry 1986; 47: 490-494
57. Povlsen UJ, Noring U, Fog R, Gerlach J. Tolerability and therapeutic effect of clozapine. Acta Psychiatr Scand 1985; 71: 176-185
58. Prien RF, Caffey EM, Klett J. Factors associated with treatment success in lithium carbonate prophylaxis. Arch Gen Psychiatry 1974; 31: 189-192
59. Puzynski S, Klosiewicz L. Valproic acid amide in the treatment of affective and schizoaffective disorders. J Affect Disord 1984; 6: 15-121
60. Romeo R, Bastianello S, Janiri L, Mauro P, Pirrongelli C. Slow-release lithium in the treatment of schizoaffective syndromes. Int J Clin Pharm Res 1985; 5: 205-211
61. Rosenthal NE, Rosenthal LN, Stallone F, Dunner DL, Fieve RR. Toward the validation of RDC schizoaffective disorder. Arch Gen Psychiatry 1980; 37: 804-810
62. Sarantidis D, Waters B. Predictors of lithium prophylaxis effectiveness. Prog Neuro-Psychopharmacol 1981; 5: 507-510
63. Sernyak MJ, Woods SW. Chronic antipsychotic use in manic-depressive illness. Psychopharmacology Bull 1993; 29: 375-381
64. Smulevitch AB, Zavidovskaya GI, Igonin AL, Mikhailova NM. The effectiveness of lithium in affective psychoses. Br J Psychiatry 1974; 125: 65-72
65. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria for a selected group of functional disorders. 3rd edn. New York: New York State Psychiatric Institute, 1977
66. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush J. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment resistant illness and a history of mania. Am J Psychiatry 1999; 156: 1164-1169
67. Swoboda E, Conca A, König P, Waanders R, Hansen M. Maintenance Electroconvulsive therapy in affective and schizoaffective disorder. Neuropsychobiology 2001; 43: 23-28
68. Taylor MA. The validity of schizoaffective disorders: Treatment and prevention studies. In: Marneros A, Tsuang MT (eds.). Schizoaffective Psychoses Berlin: Springer-Verlag, 1986: p. 94-114
69. Tohen M, Zarate CA. Antipsychotic agents and bipolar disorder. J Clin Psychiatry 1998; 59 (suppl 1): 38-48
70. Torrey EF. Prevalence studies in schizophrenia. Br J Psychiatry 1987; 150: 598-608
71. Tran PV, Tollefson GD, Sanger TM, Lu Y, Berg PH, Beasley CM. Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Br J Psychiatry 1999; 4: 15-22
72. Tress W, Haag H. Vergleichende Erfahrungen mit der rezidivprophylaktischen Lithium-Langzeitmedikation bei schizoaffektiven Psychosen. Nervenarzt 1979; 50: 524-526
73. Vieta E, Goikolea JM, Corbella B, Benabarre A, Reinares M, Martinez G, Fernandez A, Colom F, Martinez-Aran A, Torrent C. Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: Results from a 6-month, multicenter, open study. J Clin Psychiatry 2001; 62: 818-825
74. Williams PV, McGlashan TH. Schizoaffective psychosis. 1. Comparative long-term outcome. Arch Gen Psychiatry 1987; 44: 130-137
75. World Health Organization. Manual of the international statistical classification of diseases, injuries and causes of death, 8th revision. Geneva: WHO, 1965
76. World Health Organization. International statistical classification of diseases, injuries and causes of death, 9th Revision. Geneva: WHO, 1975
77. World Health Organization. The ICD-10 classification of mental and behavioural disorders. Clinical descriptions and diagnostic guidelines. Geneva: WHO, 1992
78. Zarate CA, Tohen M, Banov MD, Weiss MK, Cole JO. Is clozapine a mood stabilizer? J Clin Psychiatry 1995; 56: 108-112